Now over 20 years old (Handyside et al., 1990) , preimplantation genetic diagnosis (PGD) is considered by some to be not only an intrinsic component of prenatal genetic diagnosis (Simpson, 2009 ) but more arguably a novel way to increase pregnancy rates in assisted reproductive technology (ART). PGD remains widely practiced, despite recent controversy with respect to PGD aneuploidy testing (Mastenbroek et al., 2007; Fritz, 2008) . Much of this controversy concerns whether the theoretical attraction of transferring euploid embryos is subsumed by damage unavoidably occurring at embryo biopsy. Rigorous studies are similarly needed concerning abnormalities in live born offspring of PGD pregnancies.
In this issue of Human Reproduction, Liebaers et al. (2009) provide us with a thorough, systematic, study of PGD offspring based on a 2-month follow-up examination. The authors used the same experimental design employed in their previous cohort study of ICSI offspring (Bonduelle et al., 2002) . There were a total of 563 PGD live borns, 18 stillborns and 9 neonatal deaths. Among these, 300 live borns were from single-gene PGD with 7 stillborns and 4 neonatal deaths; the other cases followed PGD for aneuploidy testing (preimplantation genetic screening). Two-thirds were examined at the authors' center, and almost none were lost to follow-up. These investigators are unusually well aware of pitfalls encountered in comparing offspring of any ART pregnancy, PGD or not, to that in the naturally conceiving population (Simpson and Liebaers, 1996) . Bias toward overestimating neonatal anomalies in ART could arise because of increased obstetrical surveillance: ultrasound that detects anomalies not evident on physical examination, increased neonatal surveillance interval beyond that typically possible through neonatal examination and more rigorous follow-up by clinical geneticists having exceptional expertise to detect abnormalities. Thus, the absolute rate of anomalies will likely be higher than in birth defects registries. Bias toward underestimation could also arise, should cases be lost to follow-up, stillborns with anomalies not taken into account, or pregnancy terminations increased as a result of aggressive prenatal diagnosis. Major malformations must be precisely defined and distinguished from minor anomalies.
Another problem is finding valid controls for offspring of ART and ICSI, which of course are required for PGD. The proper control group would be infertile couples who become pregnant without ART, obviously unachievable (Simpson and Liebaers, 1996; Simpson and Elias, 2003) . Lacking such, it remains unclear whether any increased risk reflects the ART procedure or is due merely to underlying (heritable) reasons causing both infertility and abnormal live borns. Using a similar experimental design to that employed in the current study, the authors previously reported no differences between 70 PGD, 70 ICSI offspring and 70 naturally conceived offspring (Desmyttere et al., 2009) . The general consensus is that structural anomalies are increased perhaps 25 -30% in ART offspring (Hansen et al., 2005) . That subfertile couples (those taking .12 months to achieve pregnancy) also have anomaly rates increased over background suggests the latter is applicable (Zhu et al., 2006) . The exception might be imprinting disorders like Beckwith -Wiedemann syndrome (Lim et al., 2009) ; however, the absolute frequency of imprinting defects remains low even if relative risk is increased.
No differences were found by Liebaers et al. (2009) in structural malformations between PGD offspring and ICSI offspring-2.13 versus 3.38%, respectively. Further, there were no differences between offspring resulting from single-gene PGD and PGD aneuploidy testing, for which reason data were merged. There proved to be no differences in singletons with respect to stillborns, live borns, or neonatal deaths. In multiple gestations PGD offspring showed increased perinatal deaths, for reasons that are unclear. Updated at the 2009 Preimplantation Genetic Diagnosis International Society (PGDIS) meeting, the major congenital anomaly rate in the Reproductive Genetics Institute (Chicago) was similar-1.9% of 1230 babies (Ginsberg et al., 2009) . In no study have anomalies been disproportionately clustered in any given organ system in either cohort, further offering assurance.
Diagnostic accuracy is high, the error rate of Liebaers et al. (2009) being 0.6% after excluding a well-described case in which linkage analysis was incorrectly deduced (Sermon et al., 1998) . Rechitsky et al. (2009) reported the Reproductive Genetics Institute error rate for single-gene disorders to be 0.3% per transfer cycle among 1666 cycles involving 202 different genetic conditions. Actually, safety is to be expected. The corollary of the toti-potential nature of the early embryo dictates that removal of a single cell (or two) should cause no irreparable damage because no single cell is committed along a given developmental pathway. Loss of one or more blastomeres should not lead to an increase in anomalies in surviving offspring, even if it might lead to lower implantation rates.
Of note is that embryo biopsy practiced by the Brussels center is not necessarily that employed elsewhere. That two rather than one blastomere was often removed (Staessen et al., 2004) has previously received comment (Cohen and Grifo, 2007; Simpson, 2008) . Implantation rates appear to be lowered by removal of two blastomeres based on data from cryopreserved embryos that are thawed ; however, this does not necessarily translate to an increased frequency of anomalous live borns. Similarly, polar body biopsy followed by blastomere biopsy seemingly does not appear to decrease pregnancy rate, nor should it result in increased structural anomalies. Selection against any damaged embryo, biopsied or not, is strong.
Is this study ideal? Will the 'evidence-based' aficionados be satisfied? Of course not. A much larger sample size, namely thousands if not tens of thousands, is necessary to exclude categorically an increase limited to a single organ system. Data on chromosomal abnormalities that are not clinically obvious (e.g. 47,XXY) are limited. There is no randomization nor the ideal control. But, it is quixotic to believe that the ideal study will be forthcoming. Perfection can be the enemy of good; this study is 'as good as it gets'.
Will the 1992-2005 Brussels results remain generalizable as PGD moves in different directions? Increasingly, for example, polar body biopsy is preferred for PGD aneuploidy testing, based on a meiotic error being a more immutable abnormality of the oocyte and, hence, embryo than a mitotic (blastomere) error. The ESHRE PGD consortium thus envisions using polar body biopsy for a randomized clinical trial into whether PGD aneuploidy testing does or does not increase pregnancy rates. Data generated by Liebaers et al. (2009) should be still applicable, as already shown in the less rigorous follow-up of Ginsberg et al. (2009) . Another trend is the sequence of blastomere or blastocyst biopsy followed first by array CGH or 24 chromosome analysis, next by cryopreservation of the biopsied embryo and finally by its implantation during the subsequent cycle. Cryopreservation per se does not appear to result in increased anomalies (Takahaski et al., 2005; Wennerholm et al., 2009) but there is controversy with respect to cryopreserved ICSI embryos (Belva et al., 2008) . Few pregnancies involving cryopreserved biopsied embryos have been studied, but the 'all or none' principle should apply. Either an embryo is damaged to such an extent that it cannot survive, or no organ-specific damage occurs.
But caveats exist before counseling reassurance. Clinicians and embryologists should ask whether their skill set matches that of the reporting center. This cannot be an assumption. As expounded upon elsewhere (Munné et al., 2007a, b; Simpson, 2008) , PGD is not the purview of amateurs or the inexperienced, nor is any technical procedure. Inferential data suggest that less than fully experienced embryologists or diagnosticians may do more harm than good when performing PGD, especially PGD aneuploidy testing. In my opinion, the latter should be offered only if maternal age is 37 years, 6-8 morphologically normal embryos exist and (for recurrent abortion) evidence exists of prior aneuploidy. Considerable expertise and experience should exist before a center sanguinely counsels diagnostic accuracy and safety in live borns.
In conclusion, in experienced hands, removal of one (or more) blastomeres does not result in an increase in birth defects. By extrapolation and analogous data, the same should apply to polar body or blastocyst biopsy. PGD is highly accurate (.99%). Whatever the controversy concerning efficacy of PGD in increasing pregnancy rates, patients may be informed that PGD is safe.
